The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.
North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014
Source: http://www.pharma-market-reports.com/ GO BACK
|
|
The Company is now preparing to commercialize
the following products:
-
C-Virin – is a convenient, once-a-day oral formulation of ribavirin USP
.  - C-Pegferon –is our brand of long-lasting, pegylated-interferon-alpha-2b. This product and C-Virin will be used together for the treatment of genotype 1, 2, 3, and 4 strains of hepatitis C virus.
-
C-Vaxin – is a bivalent VLP vaccine and adjuvant combination designed to be used for the prevention of genotype-1 HCV infections or as an active-specific immunotherapy of chronic HCV disease
.  - C-Immune – is a genotype-1-specific human immune globulin (antibody) product made by donor plasma fractionation, used for passive immunotherapy of HCV patients who fail to respond to ribavirin and interferon, and will be developed for the prevention or delay of graft re-infection by HCV in liver transplant recipients whose livers have failed due to chronic HCV infection.
|
|
